Condition: Thyroid Eye Disease · Graves Orbitopathy · Endocrine System Diseases · Sponsor: Sling Therapeutics, Inc.
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
This description comes directly from the study's public registry record.
Cathy Radovich · 734-887-9192 · info@slingtx.com
Robin Schmidt · 734-887-9192 · info@slingtx.com
Always discuss trial participation with your own doctor first.
| Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
| West Virginia University Eye Institute | Morgantown, West Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06112340